The global coronary artery bypass graft market size surpassed USD 13.05 billion in 2023 and is estimated to increase from USD 14.28 billion in 2024 to approximately USD 35.17 billion by 2034. It is projected to grow at a CAGR of 9.43% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Coronary Artery Bypass Graft Market
5.1. COVID-19 Landscape: Coronary Artery Bypass Graft Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Coronary Artery Bypass Graft Market, By Method
8.1. Coronary Artery Bypass Graft Market Revenue and Volume, by Method, 2024-2034
8.1.1 Off-pump
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. On-pump
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Minimally Invasive Direct
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Coronary Artery Bypass Graft Market, By Surgical Procedure
9.1. Coronary Artery Bypass Graft Market Revenue and Volume, by Surgical Procedure, 2024-2034
9.1.1. Single CABG Surgery
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Double CABG Surgery
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Triple CABG Surgery
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Quadruple CABG Surgery
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Coronary Artery Bypass Graft Market, By End use
10.1. Coronary Artery Bypass Graft Market Revenue and Volume, by End use, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Cardiology Centers
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 11. Global Coronary Artery Bypass Graft Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Surgical Procedure (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End use (2021-2034)
Chapter 12. Company Profiles
12.1. Edwards Lifesciences Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Getinge AB
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Genesee Biomedical
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Guidant Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. LivaNova plc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Medtronic plc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novadaq Technologies Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Stryker Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample